spacer
home > epc > winter 2019 > improving quality using centralised statistical monitoring
PUBLICATIONS
European Pharmaceutical Contractor

Improving Quality Using Centralised Statistical Monitoring

As the dust begins to settle after the ICH Good Clinical Practice E6 (R2) Addendum, the importance of data oversight and integrity should still not be overlooked. It has become increasingly important to the FDA after the Addendum and likewise for the sponsor’s responsibility to ensure quality management over regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Underwood, Marketing Manager at Quanticate, has over 10 years’ experience within the life sciences industry. Originally working in operations in both clinical data management and programming, he moved into the commercial division and has been in his current role for over eight years. An integral part of Thomas’ role is product development, involving extensive research into industry regulations and the resulting technology and services these influence, such as risk-based monitoring, data quality oversight, and centralised statistical monitoring. He has a postgraduate professional diploma with the Chartered Institute of Marketing and secured Chartered Marketer status in 2014.
spacer
Thomas Underwood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Cleaning Validation: What do you need to consider to ensure a successful outcome?

RSSL

Cross contamination must be avoided in the Pharmaceutical industry at all costs and successful cleaning validation ensures that patients are not put at risk due to cross contamination. The process can be divided into a number of sections each of which must be fully understood and areas of concern addressed to ensure a successful outcome across the entire process. This spans both the manufacturing and subsequent analytical and microbological support. The data used to confirm a positive/successful cleaning validation is underpinned by the results of validated analytical methods. It is essential that these results are truly representative as patient safety is based upon the absence of equipment residues. So what are those areas of concern, what affects your ability to get a successful outcome and what do you need to consider when carrying out a Cleaning Validation exercise?
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement